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Abstract
Aims Associations have been reported between age at menarche and the later risk of gestational diabetes. However, it is not 
known whether these associations reflect differences in insulin sensitivity and/or pancreatic β-cell function in pregnancy.
Methods We examined this question in women enrolled in the prospective Cambridge Baby Growth Study who recalled their 
age at menarche in questionnaires during pregnancy. Polynomial logistic and linear regression models were used to relate 
menarche timing to the risk of gestational diabetes, both unadjusted and adjusted for the Homeostasis Model Assessments 
of insulin resistance (HOMA IR) and pancreatic β-cell function (HOMA B) at week 28 of pregnancy.
Results Age at menarche showed a U-shaped association with gestational diabetes risk (linear term: p = 9.5 × 10−4; quadratic 
term: p = 1.0 × 10−3; n = 889; overall model p = 8.1 × 10−3). Age at menarche showed a negative linear association with insulin 
resistance (HOMA IR: β = −0.13, p = 5.2 × 10−4, n = 771), which explained the relationship between age at menarche and 
gestational diabetes risk (adjusted linear term going from p = 0.03–0.08; adjusted quadratic term going from p = 0.04–0.08; 
n = 771). Age at menarche also showed a negative linear association with β-cell function (HOMA B: β = −0.11, p = 2.8 × 10−3, 
n = 771) but this did not attenuate the relationship between age at menarche and gestational diabetes (adjusted linear term 
p = 0.02; adjusted quadratic term p = 0.03, n = 771).
Conclusions These results suggest that the associations between age at menarche and risk of gestational diabetes and raised 
pregnancy glucose concentrations may be mediated by insulin resistance.
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Introduction
Many settings have observed secular trends towards a lower-
ing of average age at menarche (AAM) in the last 50 years, 
coincident with higher levels of nutrition [1]. The AAM 
appears to be dependent on both genetic and environmental 
factors [2]. The trend towards its lowering is thought to be 
related to the improved socioeconomic conditions and the 
higher prevalence of childhood obesity [3]. Possibly through 
reflecting differences in the reproductive hormonal milieu, 
changes in AAM may be important since it appears to be 
related to health in adult life through associations with risk 
of adult obesity [4], type 2 diabetes [5], asthma [6], endo-
metriosis [7], breast cancer [8] and death (by all causes [9]).
Not surprisingly given the strong links between type 2 
diabetes and gestational diabetes (GDM) and the associa-
tion between AAM and type 2 diabetes, recently AAM 
has also been found to be associated with the future risk 
of GDM in pregnancy [10–13]. As long ago as 1975 it 
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was suggested that early menarche may be linked to GDM 
[14]. In each of the studies the highest risk of GDM was in 
women with the earliest AAM. However, this association 
has not been consistently found across all populations [15]. 
In the studies where an association between AAM and 
risk of future GDM was observed, no attempt was made 
to relate AAM to the principal mechanisms of glucose 
regulation: insulin sensitivity and secretion in pregnancy. 
In the present analysis we therefore tested whether AAM 
was associated with future GDM risk and raised glucose 
concentrations in pregnancy, and how such associations 
relate to changes in indices of insulin sensitivity and pan-
creatic β-cell function/insulin secretion in the Cambridge 
Baby Growth Study. Early pregnancy-associated plasma 
protein A (PAPP-A) concentrations were also assessed in 
relation to AAM since these are potential biomarkers of 
GDM risk [16] that appear to relate to changes in insulin 
sensitivity in pregnancy [17].
Materials and methods
Cohort
The prospective Cambridge Baby Growth Study recruited 
2,229 women (and consequently their partners and babies) 
attending ultrasound clinics during early pregnancy at the 
Rosie Maternity Hospital, Cambridge, United Kingdom, 
between 2001 and 2009 [17, 18]. All study participants were 
over 16 years of age. At around 15 weeks of gestation (range 
12–18 weeks) the mothers had a blood sample collected 
for the measurement of serum PAPP-A [17]. At around 28 
weeks of gestation the mothers without known diabetes 
underwent a 75 g oral glucose tolerance test (OGTT) after 
fasting overnight. Venous blood was collected just prior to 
and 60 min. (and 120 min. after 2007) after the consumption 
of the glucose load for the measurement of plasma glucose, 
insulin and C-peptide concentrations. Capillary blood glu-
cose measurements were made at 0, 30, 60, 90, and 120 min. 
using an Abbott Freestyle Mini (Abbott Diagnostics, Maid-
enhead, UK). GDM, with a prevalence of 10.2% in the whole 
cohort, was defined here using the International Associa-
tion of Diabetes in Pregnancy Study Groups thresholds [19] 
using the 0 and 60 min. venous plasma glucose concentra-
tions as described [20].
Each study participant was given a printed questionnaire 
at recruitment to fill in and return once the pregnancy was 
completed. One of the questions asked “What age were 
you when you had your first period?” which the study 
participants tended to answer in terms of whole years. A 
total of 1273 women (57.1%) filled in and returned their 
questionnaires.
Ethics
The Cambridge Baby Growth Study was approved by the 
local ethics committee, Addenbrooke’s Hospital, Cam-
bridge, United Kingdom. All procedures followed were in 
accordance with the institutional guidelines and therefore 
the ethical standards as laid down in the 1964 Declaration of 
Helsinki and its later amendments. Written informed consent 
was obtained from all the study participants prior to their 
inclusion in the study.
Laboratory measurements
Serum PAPP-A was measured using a time-resolved fluores-
cence immunoassay as described previously [17]. Venous 
plasma glucose concentrations were measured using a rou-
tine glucose oxidase-based method. Plasma C-peptide and 
insulin concentrations were measured using Diagnostic 
System Laboratories (London, UK) ELISAs run according 
to the manufacturer’s instructions. The sensitivity of the 
C-peptide assay was 0.004 nmol/L. Its intra-assay CV was 
2.4% at 3.1 nmol/L and its equivalent inter-assay CV was 
2.7%. The sensitivity of the insulin assay was 2 pmol/L. Its 
intra-assay CV was 4.4% at 72 pmol/L and its equivalent 
inter-assay CV was 8.7%.
Calculations
The body mass index (BMI) was calculated as the self-
reported pre-pregnancy body weight divided by the height 
squared. Insulin sensitivity and pancreatic β-cell function 
(insulin secretion) were estimated using the Homeostasis 
Model Assessment (HOMA), calculated using the week 28 
circulating glucose and C-peptide concentrations using the 
online HOMA calculator [21]. Insulin secretion was quanti-
fied as the C-peptidogenic index, calculated as (C-peptide 
60  min—C-peptide 0  min)/(glucose 60  min—glucose 
0 min). The insulin secretion for the given insulin sensitiv-
ity was assessed in terms of the C-peptide disposition index, 
calculated as the C-peptidogenic index divided by the fasting 
C-peptide concentration. Equivalent indices were calculated 
using insulin instead of C-peptide concentrations but C-pep-
tide-derived variables were used in the statistical models so 
that they were not affected by hepatic insulin extraction. The 
areas under the OGTT capillary whole blood glucose curves 
(AUC) were calculated using the trapezoid rule.
Statistical analyses
The association between AAM and GDM was analysed 
using logistic regression, both unadjusted and adjusted for 
Acta Diabetologica 
1 3
covariates. Polynomial logistic regression was also used to 
test for a non-linear association as reported by Li et al. [12] 
and also apparent in other studies [11, 13, 15]. In our analy-
sis the GDM risk was fitted using Stata’s qfit function, hav-
ing already tested whether or not there was a linear relation-
ship with AAM. We then tested which additional metabolic 
parameters attenuated the linear and quadratic components 
of the GDM risk, using just a subset of the samples for 
whom we had HOMA data available.
The Shapiro–Wilk test was used to test for normality. 
Unless otherwise stated, all other data are presented as 
means (95% confidence intervals). Where regression coef-
ficients (β) are shown in analyses of continuous variables 
they are standardised throughout. Statistical analyses were 
performed using Stata 13 (StataCorp LP, College Station, 
Texas, U.S.A.). p < 0.05 was considered statistically signifi-
cant throughout.
Results
Characteristics of the study participants
In this cohort, 96.9% of the babies were of white ethnicity, 
0.8% were of mixed race, 0.6% were black (African or Car-
ibbean), 0.8% were East-Asian, and 0.9% were Indo–Asian. 
Only those mothers that returned their completed question-
naires were included in this analysis. Of these the mean 
AAM was 12.9 years and the median was 13 (interquartile 
range 12–14) years. The clinical characteristics of those 
women that were included and those that were excluded 
from the present analysis due to non-return of their ques-
tionnaires are shown in Supplementary Table 1 (Online 
Resource 1). The unadjusted birth weights were higher in 
those included in the present analysis (alongside a 2 day 
older gestational age at birth), although the difference in 
birth weight disappeared when adjustment was made for ges-
tational age. There were proportionally fewer women that 
smoked during pregnancy amongst those that were included 
in this analysis. The distribution of the AAM was normal 
(Shapiro–Wilk p = 0.9).
Association between age at menarche 
and gestational diabetes
Clinical characteristics of those study participants who 
developed GDM (9.8%) and those that did not are shown in 
Supplementary Table 2 (Online Resource 1). There was no 
significant difference in AAM between those that developed 
GDM and those that did not. In linear models with AAM as 
the independent variable there was no association between 
AAM and later GDM risk [odds ratio (OR) 0.97 (0.83, 1.13) 
per year, p = 0.7, n = 889]. However, in quadratic models 
there was a significant U-shaped association between AAM 
and GDM at week 28 [linear term OR 0.08 (0.02, 0.36) per 
year, p = 9.5 × 10−4; quadratic term OR 1.10 (1.04, 1.17), 
p = 1.0 × 10−3; n = 889; overall model pseudo  r2 = 1.7% and 
p = 8.1 × 10−3]. Relative risks for individual AAM categories 
are shown in Table 1. Restricting the analyses to the sam-
ples for which we had pre-pregnancy BMI data; there was 
still a U-shaped association between AAM and GDM risk 
[linear term OR 0.08 (0.02–0.40) per year, p = 2.0 × 10−3; 
quadratic term OR 1.10 (1.03–1.17), p = 2.4 × 10−3; 
n = 798]. AAM showed a negative linear relationship with 
pre-pregnancy BMI (β = −0.22, p = 6.0 × 10−10, n = 798) 
but addition of pregnancy BMI did not attenuate either the 
linear or quadratic terms of the association between AAM 
and GDM [adjusted linear term OR 0.08 (0.02, 0.41) per 
year, p = 2.5 × 10−3; quadratic term OR 1.10 (1.04, 1.18), 
p = 2.1 × 10−3; n = 798].
AAM showed negative linear but not quadratic asso-
ciations with both HOMA IR and B (Table 2). We tested 
whether these insulin traits attenuate the U-shaped associa-
tion between AAM and GDM risk in a subset of women for 
which we had full HOMA data available. In this subset, there 
was still a significant pre-adjustment U-shaped association 
between age at menarche and GDM, albeit weaker than in 
the full set of women due to the smaller sample size [linear 
term OR 0.14 (0.02–0.82) per year, p = 0.03, n = 771; quad-
ratic term OR 1.08 (1.01–1.16), p = 0.04]. This association 
was attenuated when adjusting for HOMA IR [linear term 
OR 0.18 (0.03–1.25) per year, p = 0.08, n = 771; quadratic 
term OR 1.07 (0.99–1.15), p = 0.08], but not when adjusting 
for HOMA B [linear term OR 0.12 (0.02–0.73) per year, 
p = 0.02, n = 771; quadratic term OR 1.08 (1.01–1.16), 
p = 0.03].
Association between age at menarche and indices 
from the week 28 oral glucose tolerance test
Summary data from the study participants’ OGTTs are shown 
in Supplementary Table 3 (Online Resource 1). In the full 
sample set AAM was associated with week 28 fasting glucose 
concentration in a U-shaped fashion (linear term β = −1.049, 
Table 1  The relative risks of GDM in pregnancy in the Cambridge 
Baby Growth Study for groups stratified by AAM
Age at 
menarche 
(years)
Gestational dia-
betes [n (%)]
Not gestational 
diabetes [n (%)]
Relative risk
8–9.9 3 (33.3) 6 (66.7) 3.7 (1.4, 9.7)
10–11.9 14 (9.6) 132 (90.4) 1.1 (0.6, 1.9)
12–13.9 42 (9.1) 422 (90.9) Reference
14–15.9 21 (8.8) 217 (91.2) 1.0 (0.6, 1.6)
16–17.9 7 (21.9) 25 (78.1) 2.4 (1.2, 4.9)
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p = 0.01; quadratic term β = 1.032, p = 0.01; n = 889) (Fig. 1). 
This relationship was non-significant in the sub-sample 
restricted to those women where HOMA data were available 
(linear term β = −0.785, p = 0.08; quadratic term β = 0.754, 
p = 0.10; n = 771), and was further weakened when adjusted 
for HOMA IR (linear term β = −0.443, p = 0.29; quadratic 
term β = 0.465, p = 0.27; n = 771). In contrast it was strength-
ened when adjusted for HOMA B (linear term β = −0.898, 
p = 0.04; quadratic term β =  0.828, p = 0.05; n = 771). Unlike 
with the fasting samples, AAM showed negative linear asso-
ciations with OGTT 60 min. glucose concentrations (Table 2), 
which persisted after adjusting for HOMA B (β = −0.100, 
p = 5.9 × 10−3, n = 763) but not after adjusting for HOMA IR 
(β = −0.064, p = 0.07, n = 763).
Association between age at menarche and serum 
PAPP‑A concentrations earlier in pregnancy
AAM was not linearly related to week 15 serum PAPP-A 
concentrations (β = −0.014, p = 0.7, n = 501; adjusted for 
the exact stage of gestation when the blood sample was col-
lected). However, there was an inverse U-shaped association 
between week 15 serum PAPP-A concentrations and AAM 
(linear term: β = 1.807, p = 0.02; quadratic term: β = −1.823, 
p = 0.02, n = 501; adjusted as above; Fig. 2).
Discussion
In this analysis we have confirmed associations between 
AAM and the subsequent higher risks of GDM. Not sur-
prisingly there were also relationships between AAM and 
raised glucose concentrations (both fasting and stimulated) 
Table 2  Linear and quadratic 
associations between AAM and 
indices derived from the OGTT 
(and related variables)
In each case the analysis was restricted to those samples where full C-peptide-derived HOMA data were 
available
OGTT-related variable n Linear regression Mixed linear/quadratic regression
Linear term Quadratic term
β p value β p value β p value
Pre-pregnancy BMI 658 −0.180 3.3 × 10−6 0.378 0.5 −0.560 0.3
Maternal height 690 0.209 3.2 × 10−8 0.442 0.4 −0.234 0.6
HOMA IR 731 −0.128 5.2 × 10−4 −0.925 0.05 0.799 0.09
HOMA B 731 −0.110 2.8 × 10−3 −0.499 0.3 0.390 0.4
OGTT 60 min glucose 723 −0.096 0.01 −0.129 0.8 0.034 0.9
Capillary glucose AUC 619 −0.068 0.09 −0.503 0.3 0.436 0.4
C-peptidogenic index 684 −0.002 1.0 −0.669 0.2 0.669 0.2
C-peptide disposition index 684 0.065 0.09 −0.170 0.7 0.235 0.6
Fig. 1  Fitted fasting glucose concentrations in week 28 of pregnancy 
by AAM in the Cambridge Baby Growth Study
Fig. 2  Fitted (natural log-transformed) PAPP-A concentrations 
around week 15 of pregnancy by AAM in the Cambridge Baby 
Growth Study
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in pregnancy. Consistent with the findings of Li et al. [12], 
the relationship between AAM and risk of GDM in our 
population was U-shaped. This pattern of relationship has 
also previously been observed between AAM and type 2 
diabetes [22], a condition closely related to GDM [23]. 
Both conditions are thought to result from a combination 
of insulin resistance and inadequate insulin secretion, with 
GDM generally just emerging at a younger age because of 
the additional physiological insulin resistance of pregnancy 
[23]. Visual inspection of results from other studies inves-
tigating links between AAM and GDM risk finds similar 
relationships to our U-shaped association even if those stud-
ies did not formally test for polynomial associations [11–13]. 
The one published study that failed to find an association 
between AAM and GDM risk tested only for a linear rela-
tionship [15]. However, on inspection of their data there 
is an apparent U-shaped relationship. Consistent with the 
study of Schoenaker et al. [11] the relationship that we found 
in the present study appeared to be independent of BMI. 
Indeed our data would suggest that the relationship between 
AAM and GDM risk relates to insulin resistance rather than 
adiposity.
In all previous studies reporting a significant association, 
earlier AAM appears to have a larger influence that later 
AAM on GDM risk [10–13]. Our data are consistent with 
this pattern. Indeed the earliest AAM group had a nearly 
fourfold higher risk of GDM relative to the median AAM 
groups, albeit that this was modelled from only a small 
number of participants. The small number of participants 
in this analysis with the earliest AAM may have led to an 
inflated relative risk of GDM and the true risk for this group 
may be closer to the lower end of the 95% confidence inter-
val. Indeed for AAM of < 10 years the risk of GDM by 
meta-analysis of our data combined with that of the other 
published studies [10–12, 15], relative to those with an 
AAM of 13 years, had an OR of 1.8 with a 95% confidence 
interval of 1.6–2.0 (unpublished observation) which is only 
slightly higher than that reported for an AAM of < 11 years 
in a recently published meta-analysis in this area, which of 
course did not include data from the present study [24]. In 
our study and those other studies showing a U-shaped rela-
tionship between AAM and GDM [11, 12, 15] there was also 
a slight increase in risk for GDM associated with late AAM. 
This increased risk was not observed in all studies [10, 13], 
but in our pooled random effects dose response meta-anal-
ysis of relevant studies it caused a significant non-linearity 
term (unpublished observation). The mechanism mediat-
ing the association between late AAM and slight increased 
GDM risk is currently unknown, but could involve changes 
in the sensitivity or secretion of some of the pregnancy fac-
tors described below.
Chen et al. [10] hypothesised that the overall relation-
ship between AAM and GDM risk would be underpinned by 
changes in concentrations of as yet unspecified hormone(s). 
Results from the current analysis would suggest that they are 
likely to be hormones that predominantly alter insulin sensi-
tivity. One such hormone could be PAPP-A since we found 
an inverse U-shaped relationship between AAM and circu-
lating PAPP-A concentrations around week 15 of pregnancy. 
Previously we reported that low PAPP-A concentrations at 
this stage of pregnancy are associated with an increased risk 
of GDM [17]. PAPP-A concentrations were also associated 
with reduced third trimester insulin sensitivity, possibly due 
to the modification of localised IGF bioactivity [25] through 
its role in cleaving IGF-binding protein 4 [26]. Other hor-
mones that could be involved in mediating the link between 
AAM and insulin resistant GDM include oestrogens [10] 
since higher concentrations in women have been linked both 
to early AAM [27–30] and increased GDM risk (when con-
sidered relative to sex hormone binding globulin concentra-
tions [31]). Leptin concentrations have also been associated 
with both AAM [32] and risk of GDM, independent of adi-
posity [33, 34]. Finally, in metabolic terms, the link between 
AAM and GDM risk may also involve triacylglycerols since 
their circulating concentrations may be related to both AAM 
[35, 36] and GDM risk [37].
The present analysis has advanced knowledge of the link 
between AAM and GDM risk in pregnancy by highlight-
ing the mediating role of insulin resistance. Our estimate of 
pancreatic β-cell function appeared to have a lesser role in 
AAM-related GDM risk. It did attenuate the OGTT C-pep-
tide disposition index association with AAM, but this is 
not surprising for an indicator of insulin secretion (relative 
to its sensitivity). The strengths of our analysis include its 
prospective nature, the availability of indices related to the 
glucose-insulin axis in the third trimester of pregnancy from 
the OGTT, and HOMA modelling using C-peptide rather 
than insulin concentrations (the former being unaffected by 
hepatic extraction). Its limitations include the small num-
ber of participants in the analysis at the extremes of AAM, 
which may have led to an inflation of the relative risks of 
GDM associated with these AAM categories (although 
there was still a significant relationship evident between 
AAM and GDM risk, albeit weakened, if the analysis was 
restricted to women with an AAM between 10 and 16 years; 
data not shown). This limitation did not substantially affect 
the overall relationship between AAM and GDM risk as 
AAM was modelled primarily as a continuous variable. A 
further limitation is that the ages at menarche were self-
reported which can be inaccurate. However, in other stud-
ies, self-reported AAM is thought to be moderately accurate 
in women with higher educational attainment [38] like the 
majority of women recruited to the Cambridge Baby Growth 
Study [39]. Finally, as is common with cohort studies that 
were not designed explicitly to test each different hypothesis 
in all of the specific studies they are used for, the number 
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of study participants in each of our statistical models varies 
due to missing data. Whilst this could theoretically intro-
duce a degree of bias into the analyses we have no actual 
evidence of this and the statistical analyses present a bio-
logically plausible explanation for the association between 
AAM and GDM risk.
In conclusion this study has confirmed the previously 
observed U-shaped association between AAM and future 
GDM risk [10–13] that is independent of pre-pregnancy 
BMI and therefore adiposity [11]. Our findings add, for the 
first time, that insulin resistance appears to mediate this rela-
tionship. Future studies should continue to investigate the 
possible hormonal mechanism(s) linking age at menarche 
to insulin resistance and subsequent risk of GDM.
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